Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
maanantai 4. marraskuuta 2019 päivittänyt: Udo Rudloff, M.D., National Cancer Institute (NCI)
Background:
- Pancreatic cancer is difficult to treat because by the time most cases are diagnosed, the tumors are too large to be removed surgically. Standard intravenous chemotherapy may shrink some of the tumor, but even with chemotherapy only about 25 percent of patients will live for 1 year following diagnosis. Several preliminary studies have shown that it is safe to give chemotherapy directly into the pancreas in the area of the tumor, and that giving gemcitabine over a longer period increases the amount of drug that is available to the tumor. Researchers are interested in studying whether giving the approved pancreatic cancer chemotherapy drug gemcitabine directly into the pancreas in the area of the cancer and at a slow rate of infusion is a safe and effective treatment.
Objectives:
- To test the safety and effectiveness of administering gemcitabine directly to a pancreatic tumor at a slow rate of infusion.
Eligibility:
- Individuals at least 18 years of age who have been diagnosed with pancreatic cancer that is currently too large to be removed surgically but has not yet spread to other organs.
Design:
- Participants will be screened with a full medical history and physical examination, blood and urine tests, and imaging studies.
- Participants will undergo pancreatic angiography and embolization, during which a catheter will be threaded into the blood vessels near the pancreas and a contrast dye will be used to show the blood vessels supplying the tumor. These blood vessels will then be surgically closed off.
- After the embolization, gemcitabine will be given as an infusion into the area around the tumor over 24 hours.
- Participants will return to the clinical center every 2 weeks after the first infusion for additional infusions of gemcitabine, using the same procedures as above. Participants will be monitored with frequent blood tests and imaging studies.
- Two weeks after the fourth treatment (course 1), participants will have more imaging studies, a physical examination, and blood tests. If the tumor is shrinking, participants will have two more courses of treatment (eight more infusions of gemcitabine).
- Participants will have followup visits every 3 months for 2 years following the last treatment and then every 6 months.
Tutkimuksen yleiskatsaus
Tila
Valmis
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
Background:
- Pancreatic cancer is the fourth leading cause of cancer death in the United States.
- Surgery offers the only chance at cure; however, less than 20% of patients are considered resectable at initial presentation.
- A common reason for being classified as unresectable is loco-regional advanced disease.
- Several phase I studies of regional administration of chemotherapy have proven safe.
- The main advantage of pancreatic cancer targeted arterial perfusion of Gemcitabine is achievement of higher local bio-available active drug levels at the tumor bed.
- The Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) trial is a phase I trial offering highly selective 24-hour intra-arterial administration of Gemcitabine via a subcutaneous port for patients with unresectable locally-advanced pancreatic cancer.
Objectives:
Primary Objective:
- To evaluate feasibility and toxicity of intra-arterial gemcitabine therapy (dose limiting toxicity (DLT)).
- To establish the maximum tolerated dose (MTD)
Secondary Objectives:
- To evaluate response rate using Response Evaluation Criteria in Solid Tumors (RECIST), positron emission tomography (PET), magnetic resonance imaging (MRI) and computed tomography (CT) perfusion criteria (European Association for the Study of the Liver (EASL))
- To determine progression free and overall survival.
- To evaluate the conversion rate from unresectable or borderline resectable to potentially resectable pancreatic cancer.
- To determine progression-free and overall survival.
- To analyze potential selection criteria to be used in future studies for patients who present with marginally unresectable or unresectable locally-advanced pancreatic cancer that might benefit from this approach.
Eligibility:
- Unresectable locally-advanced pancreatic cancer.
- 18 years old or greater with an Eastern Cooperative Oncology Group (ECOG) 0-2
- Laboratory and physical examination parameters within acceptable limits by standard of practice guidelines prior to surgery or chemotherapy.
- No extra-pancreatic disease except regional lymph nodes.
Design:
- This is a dose escalation phase-I study.
- Patients considered unresectable due to locally-advanced pancreatic cancer will receive selective arterial perfusion of gemcitabine over 24 hours via a subcutaneous indwelling port.
- Treatment will be given on Days 1 and 14. One cycle = 4 weeks for up to six cycles.
- Three to six patients will be enrolled per dose cohort.
- 18 to 36 patients in 7 cohorts will be accrued plus 6 more patients at the maximum tolerated dose (MTD over 36 months. Patients will be evaluated every 2 cycles (8 weeks). Upon progression patients will be taken off study. If no progressive disease (PD), patients will continue up to 6 cycles.
- Chemotherapy na(SqrRoot) ve patients and patients who received previously chemotherapy including gemcitabine will be allowed, as this mode of administration has better bioavailability, offer potential for better biological effect and less systemic toxicity profiles.
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
7
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
Maryland
-
Bethesda, Maryland, Yhdysvallat, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
18 vuotta - 99 vuotta (Aikuinen, Vanhempi Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Ei
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
- INCLUSION CRITERIA:
- Histologically or cytologically confirmed locally advanced pancreatic adenocarcinoma or clinical and radiographic evidence of pancreatic cancer
Note: Patients with a limited disease burden outside the pancreas, who have undergone systemic chemotherapy for metastatic disease and have achieved a complete response on the metastatic lesions of greater than or equal to 6 months, and have no evidence of disease outside the pancreas at time of enrollment, are eligible.
- Disease must be evaluable
- Disease should be deemed unresectable by the MD Anderson criteria
- Patients may be chemo naive or have received prior chemotherapy (including Gemcitabine) and/or radiation
- Greater than or equal to 18 years of age
- Must be able to understand and sign the Informed Consent Document
- Clinical performance status of Eastern Cooperative Oncology Group (ECOG) less than or equal to 2
- Life expectancy of greater than three months
- Patients of both genders must be willing to practice birth control during and for four months after receiving chemotherapy
Hematology:
- Absolute neutrophil count greater than 1300/mm(3) without the support of Filgrastim.
- Platelet count greater than 75,000/mm(3).
- Hemoglobin greater than 8.0 g/dl.
Chemistry:
- Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less or equal to 3 times the upper limit of normal, unless patient carries a biliary stent. For these patients, to account for asymptomatic, transient elevations in transaminases ('transaminitis'), serum ALT/AST may be less than or equal to 5 times the upper limit of normal provided all other eligibility parameters are met.
- Serum creatinine less than or equal to 1.8 mg/dl unless the measured creatinine clearance is greater than 60 mL/min/1.73 m(2)
- Total bilirubin less than or equal to 2 mg/dl,
- Prothrombin time (PT) within 2 seconds of the upper limit of normal or International Normalized Ratio (INR) less than or equal to 1.8
- No history of prior/other malignancies within the 2 years prior to enrollment with the exception of basal cell carcinoma
EXCLUSION CRITERIA:
- Metastatic disease including malignant ascites
- Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the chemotherapy on the fetus or infant.
- Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, heart failure
- Childs B or C cirrhosis or with evidence of severe portal hypertension by history, endoscopy, or radiologic studies
- Weight less than 40 kg
- Significant ascites, greater than 1000cc in the absence of peritoneal disease
- Concomitant medical problems that would place the patient at an unacceptable risk for the procedure
- Need for concurrent chemotherapy
- Discretion of the principal investigator (PI)
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Gemcitabine Dose Escalation
gemcitabine dose escalation
|
Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14.
One cycle = 4 weeks for up to six cycles.
Three to six patients enrolled per dose cohort.
Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of Participants With Dose Limiting Toxicity (DLT )
Aikaikkuna: Cycle 1 (4 weeks), for up to 6 cycles
|
Here is the number of participants with DLT.
DLT is defined as follows: All grade 3 or greater toxicities with the exception of Grade 3 constitutional symptoms that persist for less than 72 hours, Grade 3 and 4 myelosuppression (neutrophils and thrombocytopenia) of less than 5 days duration.
Grade 3 metabolic/laboratory events that are correctable within 24 hours.
Events that are assessed by the principal investigator as clearly unrelated to the agent will not be considered DLTs (e.g., events directly related to catheter insertion, pain related to underlying disease).
|
Cycle 1 (4 weeks), for up to 6 cycles
|
|
MTD (Maximum Tolerated Dose)
Aikaikkuna: Cycle 1 (4 weeks), for up to 6 cycles
|
The MTD is the highest dose that induces dose limiting toxicity (DLT) in no more than 2 patients among a cohort of 6 patients.
If 1 or fewer patients experience dose limiting toxicity than the dose level will define the MTD.
Only DLT's that occurred during cycle 1 of each dose level were used to determine the MTD.
|
Cycle 1 (4 weeks), for up to 6 cycles
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Response Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Aikaikkuna: Every 2 cycles (8 weeks), up to 18 weeks
|
Complete response is disappearance of all target lesions.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.
Partial response is at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
Progression is at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or the appearance of one or more new lesions.
Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum diameters while on study.
|
Every 2 cycles (8 weeks), up to 18 weeks
|
|
Response Rate Using Positron Emission Tomography (PET)
Aikaikkuna: Every 2 cycles (8 weeks), up to 18 weeks
|
Complete response is disappearance of all target lesions.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.
Partial response is at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
Progression is at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or the appearance of one or more new lesions.
Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum diameters while on study.
|
Every 2 cycles (8 weeks), up to 18 weeks
|
|
Response Rate Using Magnetic Resonance Imaging (MRI)
Aikaikkuna: Every 2 cycles (8 weeks), up to 18 weeks
|
Complete response is disappearance of all target lesions.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.
Partial response is at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
Progression is at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or the appearance of one or more new lesions.
Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum diameters while on study.
|
Every 2 cycles (8 weeks), up to 18 weeks
|
|
Response Using Computed Tomography (CT) Perfusion Criteria European Association for the Study of the Liver (EASL1)
Aikaikkuna: Every 2 cycles (8 weeks), up to 18 weeks
|
Complete response is disappearance of all target lesions.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.
Partial response is at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
Progression is at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or the appearance of one or more new lesions.
Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum diameters while on study.
|
Every 2 cycles (8 weeks), up to 18 weeks
|
|
Median Time to Progression
Aikaikkuna: From first day of treatment to the day of progression, assessed up to 221 months
|
Time to progression is the time between the first day of treatment to the day of disease progression.
Progression is defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or the appearance of one or more new lesions.
|
From first day of treatment to the day of progression, assessed up to 221 months
|
|
Median Overall Survival (OS)
Aikaikkuna: Overall survival was assessed through study completion, an average of 3 years.
|
Overall survival is defined as the time between the first day of treatment to the day of death.
|
Overall survival was assessed through study completion, an average of 3 years.
|
|
Number of Participants Who Converted From Unresectable or Borderline Resectable To Potentially Resectable Pancreatic Cancer
Aikaikkuna: 4 months
|
Resectability is defined by the MD Anderson Resectability criteria: Resectable is no extension; normal fat plane between the tumor and the artery (superior mesenteric artery (SMA)).
No extension (celiac axis/hepatic artery).
Patent (superior mesenteric vein/portal vein (SMV/PV)).
Borderline resectable is tumor abutment ≤180◦ (one half or less) of the circumference of the artery; periarterial stranding and tumor points of contact forming a convexity against the vessel improve chances of resection (SMA).
Short-segment encasement/abutment of the common hepatic artery (typically at the gastroduodenal origin) (celiac axis/hepatic artery).
Short-segment occlusion with suitable vessel above and below (SMV/PV).
Locally advanced is encased (>180◦) (SMA).
Encased and no technical option for reconstruction usually because of extension to the celiac axis/splenic/left gastric junction or the celiac origin (celiac axis/hepatic artery).
Occluded and no technical option for reconstruction (SMV/PV).
|
4 months
|
|
Number of Potential Selection Criteria to Be Used in Future Studies for Patients With Marginally Unresectable Or Unresectable Locally-Advanced Pancreatic Cancer
Aikaikkuna: up to 2.5 years
|
Number of selection criteria that can be used for unresectable pancreatic cancer.
|
up to 2.5 years
|
|
Number of Participants With Serious and Non-Serious Adverse Events
Aikaikkuna: Date treatment consent signed to date off study, approximately 2 years and 2 months and 21 days
|
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0).
A non-serious adverse event is any untoward medical occurrence.
A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned
|
Date treatment consent signed to date off study, approximately 2 years and 2 months and 21 days
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Tutkijat
- Päätutkija: Udo Rudloff, M.D., National Cancer Institute (NCI)
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Yleiset julkaisut
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
- Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001 Sep;35(3):421-30. doi: 10.1016/s0168-8278(01)00130-1. No abstract available.
- Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999 Jul;189(1):1-7. doi: 10.1016/s1072-7515(99)00075-7.
- Davis JL, Pandalai P, Ripley RT, Langan RC, Steinberg SM, Walker M, Toomey MA, Levy E, Avital I. Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial. Trials. 2011 May 19;12:129. doi: 10.1186/1745-6215-12-129.
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Keskiviikko 26. tammikuuta 2011
Ensisijainen valmistuminen (Todellinen)
Keskiviikko 23. heinäkuuta 2014
Opintojen valmistuminen (Todellinen)
Keskiviikko 23. heinäkuuta 2014
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Torstai 10. helmikuuta 2011
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Torstai 10. helmikuuta 2011
Ensimmäinen Lähetetty (Arvio)
Perjantai 11. helmikuuta 2011
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Keskiviikko 13. marraskuuta 2019
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Maanantai 4. marraskuuta 2019
Viimeksi vahvistettu
Perjantai 1. marraskuuta 2019
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Ruoansulatuskanavan sairaudet
- Neoplasmat
- Neoplasmat sivustoittain
- Endokriinisen järjestelmän sairaudet
- Ruoansulatuskanavan kasvaimet
- Endokriinisten rauhasten kasvaimet
- Haiman sairaudet
- Haiman kasvaimet
- Huumeiden fysiologiset vaikutukset
- Farmakologisen vaikutuksen molekyylimekanismit
- Infektiota estävät aineet
- Viruksenvastaiset aineet
- Entsyymin estäjät
- Antimetaboliitit, antineoplastiset
- Antimetaboliitit
- Antineoplastiset aineet
- Immunosuppressiiviset aineet
- Immunologiset tekijät
- Gemsitabiini
Muut tutkimustunnusnumerot
- 110099
- 11-C-0099
- P10764 (Muu tunniste: National Institutes of Health Clinical Center (CC))
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Joo
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Yhdysvalloissa valmistettu ja sieltä viety tuote
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .